Full history for every metric is available with a Kvantra account
Applied Molecular Transport Inc. (AMTI)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -127 | -77 | |||||
| Net profit | $m | - | -30 | -28 | -64 | -96 | -125 | -73 |
| EPS reported | $ | -3.23 | -1.86 | |||||
| Operating cashflow per share | $ | -2.42 | -2.42 | |||||
| Capex per share | $ | 0.11 | 0.11 | |||||
| FCF per share | $ | -2.52 | -2.52 | |||||
| Free cash flow | $m | -98 | -60 | |||||
| Net debt | $m | -25 | -18 | |||||
| Book value equity | $m | 61 | 16 | |||||
| Book value per share | $ | 1.57 | 0.41 | |||||
| Number of shares | m | 38.84 | 39.75 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.27 | 0.68 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.17 | -0.18 | |||||
| EV/EBITDA LTM | x | 0.07 | 0.17 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -768.97% | -1228.0% | |||||
| FCF Yield | % | -601.12% | -549.58% | |||||
| Quality | ||||||||
| ROE | % | -206.17% | -111.78% | |||||
| ROIC | % | -129.95% | -129.95% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.71 | -44.71 | |||||
| Net Debt/EBITDA | x | 0.20 | 0.20 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -153.41% | -164.48% | |||||
| Net debt/Equity | x | -0.41 | -1.11 | |||||
| Gross debt/equity | x | 0.59 | 0.08 | |||||
Company overview
Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the clinical development phase, was founded in 2010 and is based in South San Francisco, California. The firm is dedicated to discovering and advancing a pipeline of oral and respiratory biologic drug candidates, designed to address a variety of medical conditions including autoimmune, inflammatory, and metabolic diseases. Among its investigational treatments, AMT-101 stands out as the lead candidate. This orally administered, gastrointestinal (GI)-selective biologic, derived from rhIL-10, is presently in Phase II clinical trials for the management of ulcerative colitis and other related inflammatory indications. AMTI is also further developing AMT-126, another oral, GI-selective biologic that harnesses interleukin 22. This compound is currently undergoing Phase I clinical studies for the treatment of disorders stemming from impaired intestinal epithelial barrier function. The company's innovative technology platform allows for the creation and development of a broad spectrum of oral biologic therapeutic approaches, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Applied Molecular Transport Inc. (AMTI)
Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the clinical development phase, was founded in 2010 and is based in South San Francisco, California. The firm is dedicated to discovering and advancing a pipeline of oral and respiratory biologic drug candidates, designed to address a variety of medical conditions including autoimmune, inflammatory, and metabolic diseases. Among its investigational treatments, AMT-101 stands out as the lead candidate. This orally administered, gastrointestinal (GI)-selective biologic, derived from rhIL-10, is presently in Phase II clinical trials for the management of ulcerative colitis and other related inflammatory indications. AMTI is also further developing AMT-126, another oral, GI-selective biologic that harnesses interleukin 22. This compound is currently undergoing Phase I clinical studies for the treatment of disorders stemming from impaired intestinal epithelial barrier function. The company's innovative technology platform allows for the creation and development of a broad spectrum of oral biologic therapeutic approaches, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free